07:00 , Aug 8, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Acid-sensing ion channel-3 (ASIC3; ACCN3) In vitro and mouse studies suggest a peptide inhibitor of ASIC3 could help treat inflammatory and acid-induced pain. Electrophysiological...
07:00 , Aug 16, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Dermal ulcers Acid-sensing ion channel-3 (ASIC3; ACCN3) Rodent studies suggest increasing ASIC3 channel activity could help prevent dermal ulcers. An impaired pressure-induced vasodilation response is...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Flamel, Theralpha deal

The companies partnered to co-develop a controlled-release formulation of Theralpha's THA902 to treat pain. Flamel will contribute its Medusa nanogel polymer drug delivery technology, while Theralpha will use its Acid Sensing Ion Channels (ASICs) technology...
07:00 , May 5, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Acid-sensing ion channel-3 (ACCN3; ASIC3) Studies in rats suggest that inhibiting ASIC3 could help treat postoperative pain. In a rat...